How well does Longitude Capital fit your startup? Fox weighs their thesis, check size, portfolio pattern and your traction to tell you exactly how to position the conversation.
Longitude Capital pursues a venture growth strategy centered on building a balanced portfolio of clinical-stage and commercial-stage life sciences companies with clinically de-risked assets, attractive valuations relative to risk, and expected returns within three to five years. It sources opportunities through an extensive network of industry relationships and proprietary thematic research into emerging therapeutic areas. The firm uses varied investment structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, and royalties. Post-investment, it works with portfolio companies and syndicate partners to build teams, achieve operating milestones, raise capital, and pursue liquidity events.
Founder and Managing Director of Longitude Capital focused on medical technology and health solutions. Previously founded the life sciences practice at Pequot Ventures and held roles at Waste Management International, Banque Paribas, and PaineWebber.
Founder and Managing Director focused on biotechnology and health solutions. Previously co-led the life sciences practice at Pequot Ventures and held senior operating roles at Valentis, Hoffmann-La Roche, and Novartis.
Venture Partner and Founder focused on health solutions. Previously a Senior Vice President in Pequot Ventures' life sciences practice and worked at Amerindo, Vector Fund Management, and J.P. Morgan.
Managing Director and Founder of Longitude Capital who previously founded the life sciences practice at Pequot Ventures and held roles at Waste Management International, Banque Paribas, and PaineWebber. She focuses on medical technology and health solutions.
Mr. Enright· Managing Director & Founder· Menlo Park
Co-founder and Managing Director focused on biotechnology and health solutions. He previously co-led the life sciences practice at Pequot Ventures and held senior roles at Valentis, Hoffman-La Roche, and Novartis. He holds an MBA from Wharton and a BS from Stanford.
▼
MG
Mr. Galletti· Venture Partner & Founder· Menlo Park
Venture Partner and co-founder focused on health solutions. He previously worked at Pequot Ventures, Amerindo, Vector Fund Management, and J.P. Morgan. He holds an MBA from Kellogg and a BA from Princeton.
Co-founder and Managing Director focused on medical technology and health solutions. She previously founded the life sciences practice at Pequot Ventures and held roles at Waste Management International, Banque Paribas, and PaineWebber. She holds an MPA from Harvard Kennedy School and a BSc from Cornell.
Managing Director and Founder of Longitude Capital who co-led the life sciences practice at Pequot Ventures and held senior roles at Valentis, Hoffmann-La Roche, and Novartis. He focuses on biotechnology and health solutions.
Managing Director focused on medical technology who joined in 2016. Previously held strategy, finance, and operating roles at Cardinal Health, most recently as Director of North America Marketing for Cordis, and began his career at Deloitte Consulting.
Managing Director who joined in 2018 from McKinsey's pharmaceuticals and medical products practice. He focuses on biotechnology and holds an MD from Stanford.
Managing Director focused on biotechnology who joined in 2018 after serving as an Engagement Manager at McKinsey. He holds an MD from Stanford and a BS from Johns Hopkins.
▼
H
Helms· Managing Director & Chief Financial Officer· Menlo Park
Managing Director and CFO responsible for financial reporting and firm-wide finance, tax, HR, IT, and administration. She joined in 2008 from Sierra Ventures and is a licensed (inactive) CPA.
Managing Director focused on biotechnology who joined in 2018 from McKinsey & Company's pharmaceuticals and medical products practice. Holds an MD from Stanford.
Managing Director who joined in 2022 after serving as COO and CFO of GRAIL and CFO of Jazz Pharmaceuticals. He focuses on biotechnology and previously spent nearly 20 years in life sciences investment banking.
Managing Director who joined Longitude in 2016 after strategy, finance, and operating roles at Cardinal Health. He focuses on medical technology and holds a biomedical engineering degree from Duke.
Managing Director focused on medical technology who joined in 2016 after strategy, finance, and operating roles at Cardinal Health. He holds a BSE in Biomedical Engineering from Duke.
Managing Director focused on biotechnology who joined in 2022 after serving as COO and CFO of GRAIL and CFO of Jazz Pharmaceuticals. He holds an MBA and BS in Economics from Wharton.
▼
MH
Ms. Helms· Managing Director & Chief Financial Officer· Menlo Park
Managing Director and CFO responsible for the firm's fund financial reporting and day-to-day finance, tax, HR, IT, and administration. She joined in 2008 from Sierra Ventures and is a licensed (inactive) CPA.
Managing Director focused on biotechnology who joined in 2022. Previously served as COO and CFO of GRAIL and as CFO of Jazz Pharmaceuticals, and spent nearly 20 years in investment banking.
Principal focused on biotechnology who joined full-time in 2022 after serving as a Longitude Research Fellow. He earned a PhD in Biology from MIT specializing in gene editing and cancer immunology.
Vice President focused on biotechnology who joined in 2025 after fellowships with Foresite Capital, Aditum Bio, and Insight Partners. He holds a PhD from Harvard Medical School, an MD from UCSF, and a BA from Cornell.
Principal focused on biotechnology who joined full-time in 2022 after serving as a Longitude Research Fellow. Holds a PhD in Biology from MIT specializing in gene editing and cancer immunology.
Vice President focused on biotechnology who joined in 2025 after fellowships with Foresite Capital, Aditum Bio, and Insight Partners. Holds a PhD from Harvard Medical School and an MD from UCSF.
Vice President who joined in 2025 after fellowships with Foresite Capital, Aditum Bio, and Insight Partners. He holds a PhD from Harvard Medical School and an MD from UCSF and focuses on biotechnology.
Michael Wert, a Managing Director who returned to the firm after private equity at Warburg Pincus, specializes in value-based, tech-enabled care services focused on complex care delivery and payment reform.
Principal who joined full-time in 2022 after serving as a Longitude Research Fellow. He holds a PhD in Biology from MIT specializing in gene editing and cancer immunology and focuses on biotechnology.
Venture Partner focused on biotechnology who began working with the firm in 2025. He previously covered pharma and biotech at Seven Fleet Capital and Walleye Capital and worked at the FDA and Hatteras Venture Partners. He holds a PhD from UNC Chapel Hill.
Venture Partner focused on biotechnology with over 25 years of clinical drug development and medical affairs experience. She joined in 2023 after serving as CMO of Surrozen. She holds an MD and PhD in Pharmacology from the Catholic University of Leuven.
▼
MG
Marc Galletti· Venture Partner and Founder· Menlo Park
Venture Partner and Founder who previously worked in the life sciences practice at Pequot Ventures and at Amerindo, Vector Fund Management, and J.P. Morgan. He focuses on health solutions.
Venture Partner focused on biotechnology who began work with the firm in 2025. Previously a co-founding investment analyst at Seven Fleet Capital and an analyst at Walleye Capital, with prior roles at the FDA and Hatteras Venture Partners.
Venture Partner who began working with Longitude in 2025, previously a co-founding investment analyst at Seven Fleet Capital and analyst at Walleye Capital. He holds a PhD in Pharmaceutical Sciences and focuses on biotechnology.
Venture Partner with over 25 years of clinical drug development and medical affairs experience who joined in 2023 after serving as CMO of Surrozen. She holds an MD and PhD and focuses on biotechnology.
Venture Partner focused on biotechnology with over 25 years of clinical drug development and medical affairs experience. Joined in 2023 after serving as CMO of Surrozen and holding senior roles at Jazz Pharmaceuticals, Depomed, and others.
Senior Associate focused on medical technology who joined in 2024. Previously an investment banking analyst at Cowen and a private equity analyst at Montage Partners.
Senior Associate who joined in 2024 after working as an investment banking analyst in Morgan Stanley's healthcare group. She focuses on biotechnology.
▼
C
Cabreros· Director of Operations & Facilities· Menlo Park
Director of Operations & Facilities and a member of the Finance team who joined in 2017. Previously a Tax Controller at Northgate Capital and held accounting roles at ONSET Ventures and PwC.
▼
CH
Carolyn Helms· Managing Director and Chief Financial Officer· Menlo Park
Managing Director and CFO responsible for financial reporting and firm-wide finance, tax, HR, IT, and administration. She joined in 2008 after serving as Controller at Sierra Ventures and is a licensed (inactive) CPA.
Senior Associate focused on biotechnology who joined in 2024. Previously an investment banking analyst in Morgan Stanley's healthcare group covering biopharma.
Cristiana Oliveira· Head of Legal and Chief Compliance Officer· Menlo Park
Head of Legal and Chief Compliance Officer who joined in 2020 after serving as a senior associate at Weil, Gotshal & Manges. She holds a JD from UC Berkeley.
VP of People who joined in 2025 after leading Total Rewards and People Operations at GRAIL and Total Rewards at Jazz Pharmaceuticals. She is a licensed (inactive) CPA.
Senior Associate who joined in 2026 after consulting for Longitude and completing fellowships at Compound and Divergence Labs. He holds a PhD from the MIT/Harvard Health Sciences and Technology program and focuses on biotechnology.
Senior Associate focused on biotechnology who joined in 2026 after consulting for the firm and completing fellowships at Compound and Divergence Labs. He earned a PhD from the MIT/Harvard HST program.
Senior Analyst focused on biotechnology public equities who joined in 2024, previously an analyst at Deep Track Capital, Lynx1, Walleye Capital, and Columbia Threadneedle. He holds a PhD in Neurobiology from Caltech.
Senior Associate focused on biotechnology who joined in 2026 after consulting for the firm and completing fellowships at Compound and Divergence Labs. Holds a PhD from the MIT/Harvard HST program.
Executive Assistant supporting the biotechnology and medical technology teams who joined in 2007. Previously an executive assistant at Pequot Ventures.
Director of IT who joined in 2023 after roles at AllCovered, with over 15 years of experience at managed IT service providers and venture capital firms.
Johnny Hu is a principal at Menlo Ventures who invests in biotech and life science companies, focusing on novel therapeutics and new medical technologies at the earliest stages. Before Menlo, he was a vice president at Longitude Capital and previously an associate at Omega Funds, and during his Ph.D. he contributed to gene editing technologies later licensed by companies including Editas Medicine and Beam Therapeutics. He holds a Ph.D. and an A.B. in Chemical and Physical Biology from Harvard University, and an M.Phil. from the University of Cambridge, where he was a Gates Cambridge Scholar.
Director of IT who joined in 2023. Previously held engineering roles at AllCovered and has over 15 years of experience managing IT operations at managed service providers and venture capital firms.
Senior Analyst focused on public equities in biotechnology who joined in 2024. Previously an analyst at Deep Track Capital, Lynx1, Walleye Capital, and Columbia Threadneedle, and an investment banking VP at Jefferies.
Vice President of Finance who joined in 2015. Previously spent seven years at KPMG (formerly Rothstein Kass) in audit and assurance focused on life science venture capital funds.
Senior Tax Manager and member of the Finance team who joined in 2024, previously a tax manager at a16z and in tax roles at GI Partners and Pattern Energy Group.
Senior Associate focused on medical technology who joined in 2024, previously an investment banking analyst at Cowen and a private equity analyst at Montage Partners.
Senior Associate focused on biotechnology who joined in 2024, previously an investment banking analyst in Morgan Stanley's Healthcare group. She holds MS and BS degrees from Stanford.
Senior Associate who joined in 2024, previously an investment banking analyst covering medical technology at Cowen and a private equity analyst at Montage Partners. He focuses on medical technology.
Executive Assistant supporting the biotechnology and medical technology teams who joined in 2007, previously an executive assistant at Pequot Ventures.
▼
O
Oliveira· Head of Legal & Chief Compliance Officer· Menlo Park
Head of Legal and Chief Compliance Officer who joined in 2020. Previously a senior associate at Weil, Gotshal & Manges advising on M&A, securities compliance, and venture financings.
▼
RL
Rod Lim· Senior Analyst – Public Equities· Menlo Park
Senior Analyst focusing on public equities who joined in 2024, previously an analyst at several biotech long/short funds and a VP in healthcare investment banking at Jefferies. He holds a PhD in Neurobiology from Caltech.
Compliance and Legal Manager who joined in 2022 after working as a compliance consultant at ACA Global. She holds a JD from the University of San Francisco.
Senior Tax Manager and member of the Finance team who joined in 2024. Previously a tax manager at a16z and held tax roles at GI Partners, Pattern Energy Group, and PwC.
Controller who joined in 2013, previously an audit associate at Moss Adams and PricewaterhouseCoopers serving technology and life sciences companies.
▼
TC
Teresa Cabreros· Director of Operations & Facilities· Menlo Park
Director of Operations & Facilities and member of the Finance team who joined in 2017, previously a Tax Controller at Northgate Capital and in finance roles at ONSET Ventures.
▼
VG
Varun Gupta· Vice President· San Francisco Bay Areain
Varun Gupta is a biomedical engineer-turned-investor with deep expertise in optical diagnostics and GI oncology, who publicly leads major financings, joins boards, and backs AI-enhanced procedural, neuro and cardiovascular devices.
Boston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.
AI & Machine LearningBiotechHealthtechMedical Devices
Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.
BiotechSouth San Francisco, US
Tim Shannon(Director)Frederick W. Gluck(Director)Elaine V. Jones(Director)Sean McCarthy(Executive Officer, Director)Neil Exter(Director)Hoyoung Huh(Director)
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment.
Digital HealthHealthtechMedical DevicesAustin, US
Richard John Foust(Executive Officer, Director)Nelson Bunker Curnes(Executive Officer, Director)Thomas Jordan Curnes II(Executive Officer, Director)Casey Tansey(Director)Dana Mead(Director)Bill Harrington(Director)
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
JOSEPH FARMER(Executive Officer)PATRICK GERALD ENRIGHT(Director)HONGBO LU(Director)TOMAS KISELAK(Director)LEON O. MOULDER, JR.(Director)JOHN JACOB ORLOFF(Director)
Richard Lindstrom(Director)Robert E. Grant(Executive Officer, Director)Jeevan Gore(Executive Officer)Hans S. Keirstead(Director)Patrick Maxwell(Director)William Link(Chairman of the Board)
Board seatJuliet Bakker· per SEC Form D · $40.5M raise · filed Jan 2015
Darren Cai(Director)Raphael Wisniewski(Director)Michael Williamson(Executive Officer)Erik Amble(Director)Raymond W. Cohen(Executive Officer, Director)Dan L. Dearen(Executive Officer)
Board seatJuliet Bakker· per SEC Form D · $55.1M raise · filed Apr 2018
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Liam Ratcliffe(Director)Ashish Khanna(Secretary & Chief Business Officer)Terry P. Gould(Director)Wilbur H. Gantz III(Director)
Assembly Bio is a biotechnology company developing antiviral therapies for serious viral and liver diseases, including treatments for recurrent genital herpes and chronic hepatitis.
Bolt Medical develops the Bolt IVL intravascular lithotripsy system, a laser-based balloon catheter platform that fractures arterial calcium using acoustic pressure waves to treat coronary and peripheral artery disease.
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).
BiotechHealthtech
Graham Heap(President, Research and Development)Ezequiel Neimark(Head of Clinical Development)Taylor Spector(Head of Medical Affairs)Scott Stirn(Head of CMC)
Cohere Health provides a clinical intelligence platform that integrates data across healthcare workflows including utilization management, payment integrity, appeals, care management, quality, and claims operations for enterprise healthcare organizations.
AI & Machine LearningEnterprise SoftwareHealthtechBoston, US
David Barrett(Director)Amir Debourou(Director)Siva Namasivayam(Executive Officer, Director)Gary L. Gottlieb(Director)Robert Shepardson(Executive Officer)Julian Harris(Director)
Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.
Digital HealthHealthtechMedical Devices<UNKNOWN>, US
Dr. Suzanne Goh(Founder)Neil Hattangadi(Executive Officer, Director)Briana Elvaiah(Executive Officer)Michael Wert(Director)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Endogenex develops the pulsENDO system, an endoscopic medical device that applies pulsed electric field technology to the small intestine to reset metabolic signaling for people with type 2 diabetes.
FIRE1 develops NORM, an implantable medical device that lets heart failure patients monitor their heart status daily at home using a wearable belt and a smartphone app, while sharing daily readings with their medical team.
Generate Life Sciences was a reproductive, newborn stem cell, and genetic services company offering products and services to help families grow and protect their families.
Predictive Oncology (POAI) operates an AI/ML platform, CORE (Computational Research Engine), powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response and support oncology drug discovery and repurposing.
Infinant Health develops a B. infantis probiotic pharmaceutical product (INF108, building on EVC001) aimed at preventing necrotizing enterocolitis (NEC) in preterm and very low birth weight infants in NICU care.
BiotechDigital HealthHealthtechWellness & FitnessSacramento, US
Laura Stoppel(Director)Michael Johnson(Executive Officer, Director)Mike Liang(Director)Amanda Birdsey-Benson(Director)Roger Wyse(Director)Patrick Enright(Director)
IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.
B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US
Prince Nnah(Director)Ike Nnah(Executive Officer, Director)David Coppins(Executive Officer, Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures
as of Jun 2025
Fund
Vintage
Committed
Net IRR
TVPI
DPI
Longitude Venture Partners IIILPs: Los Angeles City Employees' Retirement System, Maryland State Retirement and Pension System
2016
—
16.8%
1.68x
0.96x
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘ
2 insider ownership filings (Forms 3/4/5)
at Veradermics, Inc (MANE)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
What stage does Longitude Capital invest at?
Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What is Longitude Capital's typical check size?
Longitude Capital typically writes checks of $10M – $30M.
What sectors does Longitude Capital focus on?
Longitude Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Longitude Capital located?
Longitude Capital is headquartered in Menlo Park, US.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
Bain Capital is a global alternative investment firm operating across private equity, credit, ventures, real estate, special situations, life sciences, tech opportunities, and crypto.
Pivotal Life Sciences is a global healthcare investment firm backing companies that develop high-impact therapeutics for major unmet medical needs. Pivotal bioVenture Partners is its life sciences venture capital arm.
Firms observed investing alongside Longitude Capital, from public investor directories. Shared companies are the overlap with Longitude Capital's recorded portfolio.
